Shanghai Pharmaceutical announced that Shangshi International, a wholly-owned subsidiary of Shangshi Group, the controlling shareholder of the company, increased its holdings of 800,000 H shares by 800,000 yuan on November 2, 2026, to an increase of 8.839 million yuan, accounting for 0.02% of the total share capital. After this increase in holdings, Shangshi International held 375 million H shares of the company, accounting for 10.119% of the total share capital. From November 2, 2026 to November 1, 2027, Shangshi Group plans to increase the company's H shares holdings from November 2, 2026 to November 1, 2027 through centralized bidding on the Hong Kong Stock Exchange, accounting for 0.3% to 0.6% of the total share capital. There is no fixed price range. The capital will be its own capital. Shanghai Real International promised not to reduce its holdings of the company's shares during the implementation period and within 6 months after completion of the increase in holdings.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.